Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Glioma 1

Interventions

Magnetic Resonance Spectroscopy 10X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6ulixertinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2Vemurafenib 2Thalidomide 2Paclitaxel 2Nivolumab 2LY3023414 2Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × cabiralizumab × Genitourinary × Clear all
NCT02526017 2022-03-09

FPA008-003

Five Prime Therapeutics, Inc.

Phase 1 Completed
313 enrolled 30 charts
CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡